CoChat

EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies

The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.

Abstract

Purpose: Epidermal growth factor receptor (EGFR) and VEGF(R) signaling show extensive cross-talk, providing a rationale for joint targeting of the two pathways. However, combinations of monoclonal antibodies (mAb) targeting EGFR and VEGF showed disappointing activity in patients with colorectal cancer (CRC). We speculated that inhibition of surface receptors and ligands might only partly prevent oncogenic signaling whereas small-molecule tyrosine kinase inhibitors (TKI) would also influence intracellular signaling. Experimental Design: Mice with CRC xenografts were treated with two TKIs, vargatef and afatinib, or with two mAbs, bevacizumab and cetuximab, and their influence on tumor growth, viability, in vivo DNA synthesis, and the presence of phosphorylated EGFR and VEGFR was determined. The activity of the TKIs was further characterized in CRC cells with different KRAS status. Results: Vargatef and afatinib together showed strong tumor growth inhibition toward HT-29 xenografts compared with either drug alone, which was associated with a 5-fold increase in apoptotic tumor cell death. In comparison, bevacizumab and cetuximab together were exclusively cytostatic with no more activity than either drug alone. Exposure to the two TKIs was accompanied by a marked decrease of tumor-associated intracellular phospho-VEGFR1 and phospho-EGFR, whereas similar exposure to the two mAbs had no detectable effect. A synergistic activity of vargatef plus afatinib was observed in all eight CRC cell lines examined, independent of KRAS status. Conclusions: Our results indicate that attenuation of intracellular EGFR and/or VEGF signaling is required for cytotoxic activity. These findings provide a rationale for trials of the TKIs, even in patients with mutant KRAS. Clin Cancer Res; 17(20); 6522–30. ©2011 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-11-1607

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 37 references

Cited by

See all 55

Metadata

Authors
Poindessous, V., Ouaret, D., El Ouadrani, K., Battistella, A., Mégalophonos, V. F., Kamsu-Kom, N., Petitprez, A., Escargueil, A. E., Boudou, P., Dumont, S., Cervera, P., Fléjou, J.-F., André, T., Tournigand, C., Chibaudel, B., de Gramont, A., & Larsen, A. K.
Affiliations
  • Inserm (FR)
  • Authors' Affiliations: 1Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine; 2Institut National de la Santé et de la Recherche Médicale U938; 3Université Pierre et Marie Curie (University of Paris 6); Departments of 4Pathology and 5Clinical Oncology, Hôpital Saint-Antoine, Paris, France
Venue
Clinical Cancer Research
Published
2011-10-14
Volume
17
Issue
20
Pages
6522-6530
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2171406886
Cited by
55
References
39
Citations by year
2026: 2 · 2024: 1 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 4 · 2018: 2 · 2017: 1 · 2016: 7 · 2015: 10 · 2014: 9 · 2013: 7 · 2012: 4
FWCI
3.12
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Association pour la Recherche sur le Cancer
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
colorectal cancer, EGFR, VEGFR, tyrosine kinase inhibitors, afatinib, bevacizumab, cetuximab, monoclonal antibodies, drug synergy, KRAS status, apoptosis, xenograft models
MeSH terms
Bevacizumab, Cetuximab, Afatinib, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Cell Survival, Drug Synergism, Female, Humans, Indoles, Mice, Nude, Protein-Tyrosine Kinases, Quinazolines, Colorectal Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, HT29 Cells, Xenograft Model Antitumor Assays, Receptors, Vascular Endothelial Growth Factor, Cell Proliferation, Mice, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-1607
The paper
Poindessous, V., Ouaret, D., El Ouadrani, K., Battistella, A., Mégalophonos, V. F., Kamsu-Kom, N., Petitprez, A., Escargueil, A. E., Boudou, P., Dumont, S., Cervera, P., Fléjou, J.-F., André, T., Tournigand, C., Chibaudel, B., de Gramont, A., & Larsen, A. K. (2011). EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-1607

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.